CNAT Rises On Trial Data, WMGI Boosts Forecast, RMTI Pays Price For Launch Delay

Shares of Rockwell Medical Inc. (RMTI) plunged more than 14% on Wednesday after the company said that it will be able to launch its low-cost generic active vitamin D drug Calcitriol only in the third quarter of this year due to a manufacturing issue encountered by its contract manufacturer.

from RTT - Biotech http://ift.tt/1ZfYyWT
via IFTTT